m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04157)
Name
LY2928057
Status
Phase 2
TTD Drug ID
D0IN8Z
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Solute carrier family 40 member 1 (SLC40A1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Solute carrier family 40 member 1 (SLC40A1) is a therapeutic target for LY2928057. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY2928057 through regulating the expression of Solute carrier family 40 member 1 (SLC40A1). [1], [2]
References
Ref 1 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 2 The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. doi: 10.1002/gcc.22022. Epub 2012 Oct 29.